Selective prescribing of simvastatin and atorvastatin by patient characteristics at treatment initiation over a 7-year period in Finland

European Journal of Clinical Pharmacology

Volumn 65, Issue 9, 2009, Pages 927-933

  Halava, Heli ^a   Helin Salmivaara, Arja ^a   Junnila, Jouni ^a   Huupponen, Risto ^a,b  

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Atorvastatin; Channelling; Prescribing; Simvastatin; Statins

Indexed keywords

ATORVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG PREFERENCE; DRUG UTILIZATION; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; FINLAND; GROUPS BY AGE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PRIORITY JOURNAL; SEX DIFFERENCE; TREND STUDY;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; DRUG PRESCRIPTIONS; FEMALE; FINLAND; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PYRROLES; SIMVASTATIN;

EID: 69249212385     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-009-0664-1     Document Type: Article

References (31)

1. J Larsen 2001 Changes in the utilisation of lipid-lowering drugs over a 6-year period (1993-1998) in a Danish population Eur J Clin Pharmacol 57 343 348
2. TJ Wang RS Stafford JC Ausiello CE Chaisson 2001 Randomized clinical trials and recent patterns in the use of statins Am Heart J 141 957 963
3. Nordic Medico Statistical Committee (2004) Medicines consumption in the Nordic countries 1999-2003. NOMESCO, Copenhagen
4. T Walley P Folino-Gallo P Stephens E Van Ganse 2005 Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997-2003 Br J Clin Pharmacol 60 543 551
5. Scandinavian Simvastatin Survival Study Group 1994 Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1383 1389
6. IMS Health (2008) Top-line industry data. http://www.imshealth.com/ims/ portal/front/indexC/0,2773,6599-5264-0,00.html. Accessed 11 July 2008
7. MR Law NJ Wald AR Rudnicka 2003 Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis BMJ 326 1423 30
8. Z Zhou E Rahme M Abrahamovicz JV Tu MJ Eisenberg K Humphories PC Austin L Pilote 2005 Effectiveness of statins in secondary prevention in elderly patients after myocardial infarction: an evaluation of class effect JAMC 172 1187 1195
9. SA Kamat SK Gandhi M Davidson 2007 Comparative effectiveness of rosuvastatin versus other statin therapies in patients at increased risk of failure to achieve low-density lipoprotein goals Curr Med Res Opin 23 1121 1130 Foody JM
10. AT Joyce AE Rudolph LZ Liu JS Benner 2008 Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States Clin Ther 30 195 205
11. S Schneeweiss 2007 Developments in post-marketing comparative effectiveness research Clin Pharm Ther 82 143 156
12. K Bennett M Teeling J Feely 2003 "Selective" switching from non-selective to selective non-steroidal anti-inflammatory drugs Eur J Clin Pharmacol 59 645 649
13. F Patino J Allison J Olivieri A Mudano L Juarez S Person TR Mikuls 2003 The effects of physician speciality and patient comorbidities on the use and discontinuation of coxibs Arthritis Rheum 49 293 299
14. Y Moride T Ducruet JF Boivin N Moore S Perreault S Zhao 2005 Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control study Arthritis Res Ther 7 R333 42
15. NS Rawson P Nourjah SC Grosser DJ Graham 2005 Factors associated with celecoxib and rofecoxib utilization Ann Pharmacother 39 597 602
16. National Agency for Medicines and Social Insurance Institution (2005) Finnish statistics on medicines 2004. Helsinki
17. WHO (2008) About the ATC/DDD system. http://www.whocc.no/atcddd/ Accessed 11 July 2008.
18. Statistics Finland (2009) Classification of socio-economical status. http://www.stat.fi/meta/luokitukset/index-en.html Accessed 20 April 2009
19. P Jones S Kafonek I Laurora D Hunninghake 1998 Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study) Am J Cardiol 81 582 587 (Pubitemid 28182422)
20. GG Schwartz AG Olsson MD Ezekowitz P Ganz MF Oliver D Waters A Zeiher BR Chaitman S Leslie T Stern 2001 Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial JAMA 285 1711 1718
21. PS Sever B Dahlof NR Poulter H Wedel G Beevers M Caulfield R Collins SE Kjeldsen A Kristinsson GT McInnes J Mehlsen M Nieminen E O'Brien J Ostergren ASCOT Investigators 2003 Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial Lancet 361 1149 1158 (Pubitemid 36398384)
22. HM Colhoun DJ Betteridge PN Durrington GA Hitman HA Neil SJ Livingstone MJ Thomason MI Mackness V Charlton-Menys JH Fuller 2004 Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 364 685 96
23. JR Downs M Clearfield S Weis E Whitney DR Shapiro PA Beere A Langendorfer AM Gotto Jr 1998 Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study JAMA 279 1615 1622
24. L Streja CJ Packard J Shepherd S Cobbe I Ford WOSCOPS Group 2002 Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West Of Scotland Coronary Prevention Study (WOSCOPS) Am J Cardiol 90 731 736
25. W Himmel E Lippert-Urbanke MM Kochen 1997 Are patients more satisfied when they receive a prescription? The effect of patient expectations in general practice Scand J Prim Health Care 15 118 122
26. N Britten O Ukoumunne 1997 The influence of patients' hopes of receiving a prescription on doctors' perceptions and the decision to prescribe: a questionnaire survey BMJ 315 1506 1510
27. P Lytsy R Westerling 2007 Patient expectations on lipid-lowering drugs Patient Educ Couns 67 143 150
28. S Sakshaug K Furu Karlstadt M Rønning S Skurtveit 2007 Switching statins in Norway after new reimbursement policy-a nationwide prescription study Br J Clin Pharmacol 64 476 481
29. H Ohlsson B Chaix J Merlo 2009 Therapeutic traditions, patient socioeconomic characteristics and physicians' early new drug prescribing - a multilevel analysis on rosuvastatin prescription in south Sweden Eur J Clin Pharmacol 65 141 150
30. Cholesterol Treatment Trialists' Collaborators 2005 Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins Lancet 366 1267 1278
31. PM Ridker E Danielson FA Fonseca J Genest AM Jr Gotto JJ Kastelein JUPITER Study Group, et al. 2008 Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2195 207